Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome.

Clinical epigenetics - 30 Aug 2021

Li Xiao, Xu Feng, Zhang Zheng, Guo Juan, He Qi, Song Lu-Xi, Wu Dong, Zhou Li-Yu, Su Ji-Ying, Xiao Chao, Chang Chun-Kang, Wu Ling-Yun

Abstract excerpt

BACKGROUND: BCOR (BCL6 corepressor) is an epigenetic regulator gene involved in the specification of cell differentiation and body structure development. Recurrent somatic BCOR mutations have been identified in myelodysplastic syndrome (MDS). However, the clinical impact of BCOR mutations on MDS prognosis is controversial and the response of hypomethylating agents in MDS with BCOR mutations (BCORMUT) remains...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cohort Studies
Share to DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epigenesis, Genetic

Share to Gene Expression Regulation

Share to Healthy Volunteers

Share to Myelodysplastic Syndromes

Share to Proto-Oncogene Proteins

Share to Repressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 34461985
DOI: 10.1186/s13148-021-01157-8
PMCID: PMC8404357

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome.PMID 34461985Read ↗

Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome.Semantic proximity Read ↗

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.Semantic proximity Read ↗

Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms.Semantic proximity Read ↗

[Clinical Characteristics and Prognostic Significance of BCOR/BCORL1 Gene Mutation in Patients with Myelodysplastic Syndromes].Semantic proximity Read ↗

The clinical implications of BCOR mutations in a large cohort of acute myeloid leukemia patients: a 5-year single-center retrospective study.Semantic proximity Read ↗

Bcor insufficiency promotes initiation and progression of myelodysplastic syndromeSemantic proximity Read ↗

Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDSSemantic proximity Read ↗

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.Semantic proximity Read ↗

[Molecular and clinical characteristics and prognosis of myelodysplastic neoplasms with biallelic TET2 inactivation].Semantic proximity Read ↗

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity Read ↗

Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.Semantic proximity Read ↗

DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic SyndromesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.